Apixaban/Enzalutamide Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Enzalutamide may cause your body to process apixaban differently.
What might happen:
The effects of apixaban may be increased or decreased.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) about taking these two medicines together or if you have taken enzalutamide in the previous two weeks. Your dose of apixaban may need adjusting, especially if your doctor stops your other medicine. If you experience bleeding from your gums, nosebleeds, unusual bruising, or dark stools, contact your doctor.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it.Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Eliquis (apixaban) Australian prescribing information. Bristol-Myers Squibb Australia Pty. Ltd. July 21, 2011.
- 2.Eliquis (apixaban) Canadian prescribing information. Bristol-Myers Squibb-Pfizer March 12, 2019.
- 3.Eliquis (apixaban) UK summary of product characterstics. Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House May, 2021.
- 4.Eliquis (apixaban) US prescribing information. Bristol-Myers Squibb Company April, 2021.
- 5.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 6.Shatzel JJ, Daughety MM, Olson SR, Beer TM, DeLoughery TG. Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. J Oncol Pract 2017 Nov;13(11):720-727.
- 7.Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, Minematsu T. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn 2023 Oct;50(5):365-376.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.